Assessment of Health Economics in Alzheimer’s Disease (AHEAD)Treatment with Galantamine in Sweden

被引：0
|
作者：
Frances B. Garfield
Denis Getsios
J. Jaime Caro
Anders Wimo
Bengt Winblad
机构：
[1] Caro Research Institute,Division of General Internal Medicine, Royal Victoria Hospital
[2] Caro Research,Division of Geriatric Medicine
[3] McGill University,undefined
[4] Neurotec,undefined
[5] Karolinska Institutet,undefined
来源：
PharmacoEconomics | 2002年 / 20卷
关键词：
Nursing Home; Rivastigmine; Tacrine; Galantamine; Nursing Home Care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Like other developed countries with aging populations, Sweden is expecting large increases in the prevalence of Alzheimer’s disease and corresponding escalations in the cost of care for patients with this disease. Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective in managing patients with Alzheimer’s disease in clinical trials.
引用
收藏
页码：629 / 637
页数：8
相关论文
共 50 条
  • [21] Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond
    Koola, Maju Mathew
    PSYCHIATRY RESEARCH, 2020, 293
  • [22] Treatment of Alzheimer's disease: rationale for combination therapy with galantamine and memantine
    Zarra, J.
    Schmidt, L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S545 - S545
  • [23] Naturalistic treatment of Alzheimer's disease with galantamine (REMINYL®):: The nature study
    Brodaty, H
    Woodward, M
    Boundy, KL
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S382 - S383
  • [24] APOE genotype and response to galantamine treatment in Alzheimer's disease.
    Aerssens, J
    Raeymaekers, P
    Lilienfeld, S
    Parys, W
    AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A195 - A195
  • [25] Benefits of galantamine treatment in patients with 'very mild' Alzheimer's disease
    Orgogozo, JM
    van Baelen, B
    Schwalen, S
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S329 - S329
  • [26] Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer's disease
    Marco-Contelles, J
    Rodriguez, C
    García, AG
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (05) : 575 - 587
  • [27] Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries
    Caro, J
    Salas, M
    Ward, A
    Getsios, D
    Migliaccio-Walle, K
    Garfield, F
    DRUGS & AGING, 2004, 21 (10) : 677 - 686
  • [28] Assessing the Health and Economic Impact of Galantamine Treatment in Patients with Alzheimer’s Disease in the Health Care Systems of Different Countries
    Jaime Caro
    Maribel Salas
    Alexandra Ward
    Denis Getsios
    Kristen Migliaccio-Walle
    Frances Garfield
    Drugs & Aging, 2004, 21 : 677 - 686
  • [29] HEALTH ECONOMICS AND HEALTH POLICY ISSUES IN ALZHEIMER'S DISEASE
    Rapp, T.
    JOURNAL OF NUTRITION HEALTH & AGING, 2010, 14 (08): : 630 - 632
  • [30] A naturalistic study of galantamine for Alzheimer's disease
    Brodaty, Henry
    Woodward, Michael
    Boundy, Karyn
    Barnes, Nicola
    Allen, Gabrielle
    CNS DRUGS, 2006, 20 (11) : 935 - 943
12345